← Back to Clinical Trials
Recruiting NCT05936619

NCT05936619 MindEx: A Novel, Multifocal, Cognitive Brain-Machine Interface System

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05936619
Status Recruiting
Phase
Sponsor Nader Pouratian
Condition Paralysis; Quadriplegic
Study Type INTERVENTIONAL
Enrollment 2 participants
Start Date 2026-02-20
Primary Completion 2030-05-30

Trial Parameters

Condition Paralysis; Quadriplegic
Sponsor Nader Pouratian
Study Type INTERVENTIONAL
Phase N/A
Enrollment 2
Sex ALL
Min Age 18 Years
Max Age 65 Years
Start Date 2026-02-20
Completion 2030-05-30
Interventions
Mind Extender (MindEx)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This research study is being done to develop a novel brain-computer interface (BCI) technology that can enable severely paralyzed individuals to interact with the world through direct brain-control of a computer. This technology is named MindEx (for Mind Extender). It utilizes four implanted "chips" in the human brain from which investigators can record brain activity during subjects' thoughts and decode meaningful information from this activity to be used as control signals for a computer, a laptop, or a tablet. The use of four brain regions is a significant differentiating feature and scientific innovation of this study over much prior work in this space, that typically derived control signals from one, or sometimes two brain regions. The brain regions to be used here can allow the decode of multiple variables simultaneously, including not just moment-to-moment position, but also high-level goals, intentions, decisions, scene comprehension, and error-related signals involved in natural human behavior. The research is being done through a prospective, longitudinal, single-arm early feasibility study to examine the safety and effectiveness of using MindEx to provide the user an intuitive, efficient, and accurate ability to control multiple applications on a computer interface such as a word processor, a paint application, or to play simple video games. Such versatility could greatly improve the autonomy and quality of life of severely paralyzed individuals. Two subjects will be enrolled, each implanted with MindEx for a period of at least 53 weeks and up to 313 weeks. The study is expected to take at least one year and up to six years in total.

Eligibility Criteria

Inclusion Criteria: * Paralysis resulting from cervical spinal cord injury (SCI), brainstem stroke (ischemic or hemorrhagic), or amyotrophic lateral sclerosis (ALS) * Provide informed consent * Understand and comply with instructions, if necessary, with the aid of a translator * Communicate via speech or other means * Surgical clearance * Life expectancy greater than 12 months * Travel to study locations up to five days per week for the duration of the study * Caregiver monitor for surgical site complications and behavioral changes on a daily basis * Psychosocial support system * Stable ventilator status Exclusion Criteria: * Presence of memory problems * Intellectual impairment * Psychotic illness or chronic psychiatric disorder, including major depression if untreated * Poor visual acuity * Pregnancy * Active infection or unexplained fever * Scalp lesions or skin breakdown * HIV or AIDS infection * Active cancer or chemotherapy * Diabetes * Autonomic dysreflexia * History of seizure

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology